Tumor BRCA testing can reveal a high tumor mutational burden related to POLE pathogenic variants.
Gynecologic Oncology Reports
Villy, M-C MC; Masliah-Planchon, J J; Melaabi, S S; Trabelsi Grati, O O; Girard, E E; Bataillon, G G; Vincent-Salomon, A A; Le Gall, J J; Golmard, L L; Stoppa-Lyonnet, D D; Bieche, I I; Colas, C C
Publication Date: 2021-08
Variant appearance in text: BRCA2: 3337G>T; Glu1113*